₹140 crore in the lockdown period.The PE firm has invested ₹70 crore each in ophthalmology hospital chain Sharp Sight and Pune-based Murli Krishna Pharma Pvt.
Ltd, a formulations maker that focuses on developing novel drug delivery system (NDDS) products."Through its strong technical and R&D capabilities, Murli Krishna Pharma has established itself as a player of repute in manufacturing of complex pharmaceutical formulations.